Factors associated with and impact of open conversion on the outcomes of minimally invasive left lateral sectionectomies: An international multicenter study.


Journal

Surgery
ISSN: 1532-7361
Titre abrégé: Surgery
Pays: United States
ID NLM: 0417347

Informations de publication

Date de publication:
08 2022
Historique:
received: 11 02 2022
revised: 16 03 2022
accepted: 25 03 2022
pubmed: 11 6 2022
medline: 19 7 2022
entrez: 10 6 2022
Statut: ppublish

Résumé

Despite the rapid advances that minimally invasive liver resection has gained in recent decades, open conversion is still inevitable in some circumstances. In this study, we aimed to determine the risk factors for open conversion after minimally invasive left lateral sectionectomy, and its impact on perioperative outcomes. This is a post hoc analysis of 2,445 of 2,678 patients who underwent minimally invasive left lateral sectionectomy at 45 international centers between 2004 and 2020. Factors related to open conversion were analyzed via univariate and multivariate analyses. One-to-one propensity score matching was used to analyze outcomes after open conversion versus non-converted cases. The open conversion rate was 69/2,445 (2.8%). On multivariate analyses, male gender (3.6% vs 1.8%, P = .011), presence of clinically significant portal hypertension (6.1% vs 2.6%, P = .009), and larger tumor size (50 mm vs 32 mm, P < .001) were identified as independent factors associated with open conversion. The most common reason for conversion was bleeding in 27/69 (39.1%) of cases. After propensity score matching (65 open conversion vs 65 completed via minimally invasive liver resection), the open conversion group was associated with increased operation time, blood transfusion rate, blood loss, and postoperative stay compared with cases completed via the minimally invasive approach. Male sex, portal hypertension, and larger tumor size were predictive factors of open conversion after minimally invasive left lateral sectionectomy. Open conversion was associated with inferior perioperative outcomes compared with non-converted cases.

Sections du résumé

BACKGROUND
Despite the rapid advances that minimally invasive liver resection has gained in recent decades, open conversion is still inevitable in some circumstances. In this study, we aimed to determine the risk factors for open conversion after minimally invasive left lateral sectionectomy, and its impact on perioperative outcomes.
METHODS
This is a post hoc analysis of 2,445 of 2,678 patients who underwent minimally invasive left lateral sectionectomy at 45 international centers between 2004 and 2020. Factors related to open conversion were analyzed via univariate and multivariate analyses. One-to-one propensity score matching was used to analyze outcomes after open conversion versus non-converted cases.
RESULTS
The open conversion rate was 69/2,445 (2.8%). On multivariate analyses, male gender (3.6% vs 1.8%, P = .011), presence of clinically significant portal hypertension (6.1% vs 2.6%, P = .009), and larger tumor size (50 mm vs 32 mm, P < .001) were identified as independent factors associated with open conversion. The most common reason for conversion was bleeding in 27/69 (39.1%) of cases. After propensity score matching (65 open conversion vs 65 completed via minimally invasive liver resection), the open conversion group was associated with increased operation time, blood transfusion rate, blood loss, and postoperative stay compared with cases completed via the minimally invasive approach.
CONCLUSION
Male sex, portal hypertension, and larger tumor size were predictive factors of open conversion after minimally invasive left lateral sectionectomy. Open conversion was associated with inferior perioperative outcomes compared with non-converted cases.

Identifiants

pubmed: 35688742
pii: S0039-6060(22)00221-5
doi: 10.1016/j.surg.2022.03.037
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

617-624

Investigateurs

Chung-Yip Chan (CY)
Nicholas Syn (N)
Mikel Prieto (M)
Henri Schotte (H)
Celine De Meyere (C)
Felix Krenzien (F)
Moritz Schmelzle (M)
Kit-Fai Lee (KF)
Diana Salimgereeva (D)
Ruslan Alikhanov (R)
Lip Seng Lee (LS)
Jae Young Jang (JY)
Kevin P Labadie (KP)
Masayuki Kojima (M)
Yutaro Kato (Y)
Asmund Avdem Fretland (AA)
Jacob Ghotbi (J)
Fabricio Ferreira Coelho (FF)
Jaime Arthur Pirola Kruger (JA)
Victor Lopez-Lopez (V)
Paolo Magistri (P)
Bernardo Dalla Valle (BD)
Margarida Casellas I Robert (M)
Kohei Mishima (K)
Giuseppe Maria Ettorre (GM)
Federico Mocchegiani (F)
Prashant Kadam (P)
Franco Pascual (F)
Mansour Saleh (M)
Alessandro Mazzotta (A)
Roberto Montalti (R)
Mariano Giglio (M)
Boram Lee (B)
Mizelle D'Silva (M)
Phan Phuoc Nghia (PP)
Chetana Lim (C)
Qu Liu (Q)
Eric C Lai (EC)

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Hao Ping Wang (HP)

Department of Surgery, Chang Gung Memorial Hospital, Kaohsiung, Taiwan.

Chee Chien Yong (CC)

Department of Surgery, Chang Gung Memorial Hospital, Kaohsiung, Taiwan.

Andrew G R Wu (AGR)

Department of Hepatopancreatobiliary and Transplant Surgery, Singapore General Hospital, Singapore.

Daniel Cherqui (D)

Department of Hepatobiliary Surgery, Assistance Publique Hopitaux de Paris, Centre Hepato-Biliaire, Paul-Brousse Hospital, Villejuif, France.

Roberto I Troisi (RI)

Department of Clinical Medicine and Surgery, Division of HPB, Minimally Invasive and Robotic Surgery, Federico II University Hospital Naples, Naples, Italy.

Federica Cipriani (F)

Hepatobiliary Surgery Division, IRCCS San Raffaele Hospital, Milan, Italy.

Davit Aghayan (D)

The Intervention Centre and Department of HPB Surgery, Oslo University Hospital, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Marco V Marino (MV)

General Surgery Department, Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy and Oncologic Surgery Department, P. Giaccone University Hospital, Palermo, Italy.

Andrea Belli (A)

Department of Abdominal Oncology, Division of Hepatopancreatobiliary Surgical Oncology, National Cancer Center- IRCCS-G, Pascale, Naples, Italy.

Adrian K H Chiow (AKH)

Hepatopancreatobiliary Unit, Department of Surgery, Changi General Hospital, Singapore.

Iswanto Sucandy (I)

Digestive Health Institute, AdventHealth Tampa, Tampa, FL.

Arpad Ivanecz (A)

Department of Abdominal and General Surgery, University Medical Center Maribor, Maribor, Slovenia.

Marco Vivarelli (M)

HPB Surgery and Transplantation Unit, United Hospital of Ancona, Department of Sperimental and Clinical Medicine Polytechnic University of Marche. Ancona, Italy.

Fabrizio Di Benedetto (F)

Hepatopancreatobiliary Surgery and Liver Transplant Unit, University of Modena and Reggio Emilia, Modena, Italy.

Sung-Hoon Choi (SH)

Department of General Surgery, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea.

Jae Hoon Lee (JH)

Department of Surgery, Division of Hepato-Biliary and Pancreatic Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

James O Park (JO)

Department of Surgery, University of Washington Medical Center, Seattle, WA.

Mikel Gastaca (M)

Hepatobiliary Surgery and Liver Transplantation Unit, Biocruces Bizkaia Health Research Institute, Cruces University Hospital, University of the Basque Country, Bilbao, Spain.

Constantino Fondevila (C)

General and Digestive Surgery, Hospital Clinic, IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Spain; General and Digestive Surgery, Hospital Universitario La Paz, IdiPAZ, CIBERehd, Madrid, Spain.

Mikhail Efanov (M)

Department of Hepato-Pancreato-Biliary Surgery, Moscow Clinical Scientific Center, Moscow, Russia.

Fernando Rotellar (F)

HPB and Liver Transplant Unit, Department of General Surgery, Clinica Universidad de Navarra, Universidad de Navarra, Pamplona, Spain & Institute of Health Research of Navarra (IdisNA), Pamplona, Spain.

Gi-Hong Choi (GH)

Division of Hepatopancreatobiliary Surgery, Department of Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.

Ricardo Robles Campos (RR)

Department of Surgery, Virgen de la Arrixaca University Hospital, Murcia, Spain.

Xiaoying Wang (X)

Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.

Robert P Sutcliffe (RP)

Department of Hepatopancreatobiliary and Liver Transplant Surgery, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.

Johann Pratschke (J)

Department of Surgery, Campus Charité Mitte and Campus Virchow-Klinikum, Charité-Universitätsmedizin, Corporate Member of Freie Universität Berlin, and Berlin Institute of Health, Berlin, Germany.

Chung Ngai Tang (CN)

Department of Surgery, Pamela Youde Nethersole Eastern Hospital, Hong Kong SAR, China.

Charing C Chong (CC)

Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, New Territories, Hong Kong SAR, China.

Mathieu D'Hondt (M)

Department of Digestive and Hepatobiliary/Pancreatic Surgery, Groeninge Hospital, Kortrijk, Belgium.

Andrea Ruzzenente (A)

General and Hepatobiliary Surgery, Department of Surgery, Dentistry, Gynecology and Pediatrics University of Verona, GB Rossi Hospital, Verona, Italy.

Paolo Herman (P)

Liver Surgery Unit, Department of Gastroenterology, University of Sao Paulo School of Medicine, Sao Paulo, Brazil.

T Peter Kingham (TP)

Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.

Olivier Scatton (O)

Department of Digestive, HBP and Liver Transplantation, Hopital Pitie-Salpetriere, Sorbonne Universite, Paris, France.

Rong Liu (R)

Faculty of Hepatopancreatobiliary Surgery, The First Medical Center of Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.

Alessandro Ferrero (A)

Department of General and Oncological Surgery, Mauriziano Hospital, Turin, Italy.

Giovanni Battista Levi Sandri (GB)

Division of General Surgery and Liver Transplantation, S. Camillo Hospital, Rome, Italy.

Olivier Soubrane (O)

Department of Digestive, Oncologic and Metabolic Surgery, Institute Mutualiste Montsouris, Universite Paris Descartes, Paris, France.

Alejandro Mejia (A)

The Liver Institute, Methodist Dallas Medical Center, Dallas, TX.

Santiago Lopez-Ben (S)

Hepatobiliary and Pancreatic Surgery Unit, Department of Surgery, Dr. Josep Trueta Hospital, IdIBGi, Girona, Spain.

Jasper Sijberden (J)

Department of Surgery, Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy.

Kazuteru Monden (K)

Department of Surgery, Fukuyama City Hospital, Hiroshima, Japan.

Go Wakabayashi (G)

Center for Advanced Treatment of Hepatobiliary and Pancreatic Diseases, Ageo Central General Hospital, Saitama, Japan.

Atsushi Sugioka (A)

Department of Surgery, Fujita Health University School of Medicine, Aichi, Japan.

Tan-To Cheung (TT)

Department of Surgery, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China.

Tran Cong Duy Long (TCD)

Department of HPB Surgery, University Medical Center, University of Medicine and Pharmacy, Ho Chi Minh City, Vietnam.

Bjorn Edwin (B)

The Intervention Centre and Department of HPB Surgery, Oslo University Hospital, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Ho-Seong Han (HS)

Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul, Korea.

David Fuks (D)

Department of Digestive, Oncologic and Metabolic Surgery, Institute Mutualiste Montsouris, Universite Paris Descartes, Paris, France.

Luca Aldrighetti (L)

Hepatobiliary Surgery Division, IRCCS San Raffaele Hospital, Milan, Italy.

Mohamed Abu Hilal (M)

Department of Surgery, Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy; Department of Surgery, University Hospital Southampton, United Kingdom.

Brian K P Goh (BKP)

Department of Hepatopancreatobiliary and Transplant Surgery, Singapore General Hospital and National Cancer Center Singapore, Singapore; Duke-National University of Singapore Medical School, Singapore. Electronic address: bsgkp@hotmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH